rt form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.









BOSTON & TORONTO--(BUSINESS WIRE)--Cybin Inc. (the “Company”) doing business as Helus Pharma™(Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP.

“Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of diffe
=*=*=*=*=*=
当前为第2/11页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页